Quantum BioPharma Valuation
| QNTM Stock | 4.51 0.03 0.66% |
At this time, the company appears to be overvalued. Quantum BioPharma holds a recent Real Value of USD3.65 per share. The prevailing price of the company is USD4.51. Our model determines the value of Quantum BioPharma from analyzing the company fundamentals such as Return On Equity of -0.64, price to book of 0.55 X, and Shares Outstanding of 1.55 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.5527 | Enterprise Value 3.5 M | Enterprise Value Ebitda (1.57) | Price Sales 91.8563 | Enterprise Value Revenue 98.5599 |
Overvalued
Today
Please note that Quantum BioPharma's price fluctuation is extremely dangerous at this time. Calculation of the real value of Quantum BioPharma is based on 3 months time horizon. Increasing Quantum BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Quantum stock is determined by what a typical buyer is willing to pay for full or partial control of Quantum BioPharma. Since Quantum BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Quantum Stock. However, Quantum BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.51 | Real 3.65 | Hype 5.73 |
The intrinsic value of Quantum BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Quantum BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Quantum BioPharma helps investors to forecast how Quantum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Quantum BioPharma more accurately as focusing exclusively on Quantum BioPharma's fundamentals will not take into account other important factors: Quantum BioPharma Cash |
|
Quantum BioPharma Total Value Analysis
Quantum BioPharma is at this time anticipated to have valuation of 3.47 M with market capitalization of 6.17 M, debt of 300.55 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Quantum BioPharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.47 M | 6.17 M | 300.55 K |
Quantum BioPharma Asset Utilization
One of the ways to look at asset utilization of Quantum is to check how much profit was generated for every dollar of assets it reports. Quantum BioPharma holds a negative application of assets of -0.36 pct., losing USD0.003612 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Quantum BioPharma shows how discouraging it operates for each dollar spent on its assets.Quantum BioPharma Ownership Allocation
Quantum BioPharma holds 14.1 pct. of its outstanding shares held by insiders and 1.54 pct. owned by third-party entities.Quantum BioPharma Profitability Analysis
Net Loss for the year was (17.9 M) with profit before overhead, payroll, taxes, and interest of 0.About Quantum BioPharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Quantum BioPharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Quantum BioPharma based exclusively on its fundamental and basic technical indicators. By analyzing Quantum BioPharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Quantum BioPharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Quantum BioPharma. We calculate exposure to Quantum BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Quantum BioPharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.7 M | -1.7 M |
Quantum BioPharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Quantum BioPharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 605.8 K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.